drugset / Trial / NCT05951816
A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
Phase 1
Unknown
35 enrolled
University of Tennessee Graduate School of Medicine
Attralus, Inc. · collab
RandomizedSingle-groupOpen-labelDiagnostic
Summary
This study will investigate 99mTc-p5+14, an amyloid-reactive synthetic peptide, p5+14, radiolabeled with technetium-99m, as a radiotracer for detecting paamyloid deposits in patients with AL or ATTR-associated systemic amyloidosis, notably with cardiac involvement.
Timeline
- Start
- 2023-07
- Primary completion
- 2024-12
- Completion
- 2025-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 99mTc-p5+14 | Peptide | 1 mg | Intravenous |
| Subject | 99mTc-p5+14 | Peptide | 20 unknown | Intravenous |
| Background | 99mTc-Pyrophosphate | Diagnostic / imaging agent | 20 unknown | — |